✦ For YouGeopoliticsTechFinanceHealthEnergySportsCulture◆ SN Last Week★ Saved

Cramer: 27% Biotech Rally Leads Stocks Working Beyond Tech

By CNBC · Summarized & edited by · 2026-07-20
Cramer: 27% Biotech Rally Leads Stocks Working Beyond Tech

Get the Finance newsletter

Daily finance — markets, central banks, M&A, the prints that move money. Free.

Why it matters: Cramer is reframing the selloff as targeted market discipline, not systemic weakness: the SPDR Biotech ETF is up 27% YTD, Wells Fargo is restructuring toward higher-margin M&A revenue, and the memory unwind is driven by forced hedge-fund selling rather than deteriorating fundamentals. If non-tech sectors keep delivering easy wins while tech stays punished, investors overweight in tech face the first real risk of prolonged relative underperformance, with capital rotation accelerating the divergence.

Share this story

More finance → Read original →

Get the Finance newsletter

Curated finance stories, every morning. Free.

No spam. Unsubscribe anytime.